REM sleep behavior disorder: update on diagnosis and management

Area of Science:

• Neurology
• Sleep Medicine
• Neurodegenerative Diseases

Background:

• REM sleep behavior disorder (RBD) is characterized by loss of skeletal muscle atonia during REM sleep, leading to dream-enacting behaviors.
• RBD is strongly associated with synucleinopathies, including Parkinson's disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB).
• Early diagnosis of RBD is critical for initiating neuroprotective strategies before the onset of significant motor and cognitive symptoms.

Purpose of the Study:

• To highlight the importance of understanding RBD for predicting neurodegenerative diseases.
• To outline diagnostic methods for RBD, emphasizing clinical history and polysomnography (PSG).
• To discuss current and future therapeutic approaches for RBD.

Main Methods:

• Clinical assessment including detailed patient and bed partner history, and review of home videos.
• Polysomnography (PSG) to objectively verify loss of muscle atonia during REM sleep (REM without atonia - RWA).
• Adherence to AASM Manual standards for PSG acquisition and analysis, reporting RWA percentage.

Main Results:

• PSG is essential for confirming RBD diagnosis and differentiating it from other sleep disorders.
• PSG findings, specifically the percentage of REM sleep epochs meeting RWA criteria, aid in distinguishing RBD patients.
• PSG helps exclude conditions that may mimic RBD symptoms, such as sleep apnea or nocturnal seizures.

Conclusions:

• Accurate diagnosis of RBD through clinical evaluation and PSG is vital for early intervention in synucleinopathies.
• Environmental safety measures and pharmacological treatments are current management strategies for RBD.
• The development of neuroprotective therapies represents a key future direction for RBD treatment.